AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Extracorporeal Photopheresis in Sezary Syndrome

Recruitingn/aAges 18 Years - 100 YearsAllOleg E. Akilov, MD, PhD
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment. 20 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months. Each patient will donate 5 samples to determine immune responses in peripheral blood. Additional clinical assessments will be a modified skin weighted assessment and flow cytometry at baseline and months 3 and 6. A CT scan will be obtained at baseline and only repeated if pathology is present at baseline. The tumor microenvironment will be studied by comparing transcriptomics of the blood samples before, 1 day after first ECP treatment, cycle 1, 1, 3 and 6 months after ECP treatment by scRNAseq (5 samples total per patient ).

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Patient with an established diagnosis of Sezary syndrome (stage IVA1) 2. Patients amenable for ECP 3. The patient must have a minimum wash-out period of 3 weeks between the last dose of prior systemic therapy 4. Patients should have recovered from all adverse events related to prior therapy to โ‰ค grade 1 5. Signed informed consent form prior to any protocol-specific procedures. Exclusion Criteria: 1. Visceral metastasis of lymphoma 2. Concomitant administration of radiotherapy or systemic anti-cancer therapy including but not restricted to: chemotherapy, biological agents, or immunotherapy 3. Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection. 4. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol. 5. Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document. 6. Patients with known allergy to Methoxsalen or heparin (as part of SOC ECP procedure). 7. Patients who are pregnant. -
๐Ÿ’Š

What it tests

  • Extracorporeal photopheresis (ECP)
  • Methoxsalen Injection
๐Ÿ“

Where

3 sites
Emory University School of Medicine
Atlanta, United States
Cutaneous Translational Research Program - Johns Hopkins Medicine
Baltimore, United States
University of Pittsburgh Medical Center
Pittsburgh, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy